Amphetamine and dextroamphetamine and Lisdexamfetamine interaction

Amphetamine and dextroamphetamine and Lisdexamfetamine: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Amphetamine and dextroamphetamine (Adderall XR) label · effective 2026-04-30

Major

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive…

Contraindicationsby drug classView label on DailyMed

From the Lisdexamfetamine (Lisdexamfetamine Dimesylate) label · effective 2026-05-22

Major

Lisdexamfetamine dimesylate capsules are contraindicated in patients with: • Known hypersensitivity to amphetamine products or other ingredients of lisdexamfetamine dimesylate capsules.

Contraindicationsnames Amphetamine and dextroamphetamineView label on DailyMed
Major

• Known hypersensitivity to amphetamine products or other ingredients in lisdexamfetamine dimesylate capsules ( 4 )

Contraindicationsnames Amphetamine and dextroamphetamineView label on DailyMed
Major

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,…

Warnings and precautionsnames Amphetamine and dextroamphetamineView label on DailyMed
Major

CYP2D6 Inhibitors Clinical Impact The concomitant use of lisdexamfetamine dimesylate and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of lisdexamfetamine dimesylate compared to the use of the drug alone and increase the risk of serotonin syndrome.

Drug interactionsnames Amphetamine and dextroamphetamineView label on DailyMed
Moderate

The co-administration with cytochrome P450 2D6 (CYP2D6) inhibitors may also increase the risk with increased exposure to the active metabolite of lisdexamfetamine dimesylate (dextroamphetamine).

Warnings and precautionsnames Amphetamine and dextroamphetamineView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.